Scientific deep-dive
Semaglutide for Alcohol Use Disorder: Read the Placebo Arm
Heavy drinking days fell 41.1 points on semaglutide and 26.4 points on placebo. The drug's effect is the 13.7-point difference, and it is real, significant and a third of the number that will be quoted.
A 2026 randomized trial gave weekly semaglutide or placebo to 108 people with both alcohol use disorder and obesity. Heavy drinking days fell by 41.1 percentage points in the semaglutide group. That figure is the one likely to be quoted, and it is the wrong one. The placebo group improved by 26.4 points, so the effect attributable to the drug is 13.7.[1]
The result, stated properly
| Group | Change | What it means |
|---|---|---|
| Semaglutide | −41.1 (95% CI −48.7 to −33.5) | The number that will be quoted |
| Placebo | −26.4 (95% CI −34.1 to −18.6) | The number that will not be |
| Treatment difference | −13.7 (95% CI −22.0 to −5.4), p=0.0015 | The effect of the drug |
The result is real. The confidence interval comfortably excludes zero, and the trial also reported substantial effects on multiple secondary alcohol-related and physical outcomes.[1] A 13.7 point reduction in heavy drinking days is a meaningful clinical effect in a condition where treatments are few and modest.
The same trap in another trial
The placebo arm also did much of the work behind the headline number in the fatty liver trial: steatohepatitis resolved in 62.9% on semaglutide and in 34.3% on placebo.
Where being watched helps, as with drinking, the drug’s contribution is a fraction of the raw change.
The pattern is not a quirk of these two studies. Any condition where being watched helps (drinking, eating, adherence, symptom scores) will produce a large placebo response, and the drug’s contribution will be a fraction of the raw change.
How far this generalizes
- 108 participants, at a single center in Denmark. Small, and one health system.
- Everyone had obesity as well as alcohol use disorder. Whether the effect holds in people with alcohol use disorder and a normal BMI is untested, and it matters, because weight loss itself may be part of the mechanism.
- All were treatment-seeking. People who volunteer for an alcohol trial are not a random sample of people who drink heavily.
- 81% completed the intervention, which is good for this field and still leaves a fifth unaccounted for.
The direction is consistent with a growing body of preclinical and clinical work suggesting GLP-1 receptors are involved in reward and craving, which we cover in GLP-1s and substance use. A small randomized trial in people who smoke (24 participants) missed both its primary endpoints,[2] so the effect may not be uniform across substances. For opioids there is no randomized trial yet, only records data on GLP-1s and opioid use disorder, which links a prescription to fewer overdoses.
What not to do with this
It is, though, an encouraging result in a field that badly needs them, and one to raise with a doctor if it describes your situation.
Frequently Asked Questions
References
- 1.Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial The Lancet. 2026. PMID: 42070571.
- 2.Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial JAMA Network Open. 2026. PMID: 42189538.
Compare the sellers
Related research
GLP-1 Drugs and Quitting Smoking: What the Trials Actually Tested
The largest randomized trial found a GLP-1 added nothing to quit rates (63% against 65% on placebo) while holding post-cessation weight for as long as it was taken. A year later that advantage had gone too.
7 min read
GLP-1 Drugs and Opioid Use Disorder: What the Records Data Shows
Across 503,747 people with opioid use disorder, a GLP-1 or GIP prescription carried an adjusted overdose rate ratio of 0.60. In methadone-treated patients it was associated with a higher rate of remission. No randomized trial exists.
6 min read
GLP-1 Drugs for PCOS: Eleven Trials, and Two Analyses That Disagree
No GLP-1 is approved for PCOS anywhere. The randomized evidence is eleven trials: a low-certainty weight effect, better insulin sensitivity than metformin, and reproductive outcomes two meta-analyses grade differently.
8 min read
GLP-1 Drugs and Eating Disorders: Two Questions, One Studied
Five studies covering 182 people make up the whole meta-analytic evidence base in binge eating disorder. What happens when these drugs reach someone with a restrictive eating disorder has never been studied at all.
6 min read
How Long Is the Evidence, Actually?
These are indefinite treatments. In the largest randomized trial at the weight indication, the mean time on the drug was 34.2 months. What the long trials ran for, and what a short evidence base does and does not mean.
7 min read
GLP-1 Drugs and Addiction: A Huge Signal, and a Trial That Missed
A 524,817-person cohort found fewer new substance use disorders of every kind measured. A randomized trial in people who smoke then missed both its primary endpoints. Both landed in 2026.
7 min read
Where to get semaglutide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
From $79/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →